News

AddToAny

Google+ Facebook Twitter Twitter

Vaccine to treat lung cancer

A first-of-its-kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer.

AST-VAC2 is a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

Cancer Research UK will manage the initial clinical development of AST-VAC2, which is a promising immunotherapy candidate that is derived from a standardised human embryonic stem cell line.

If shown to be safe and effective, it’s hoped that AST-VAC2 could be used as an additional treatment for patients who no longer have advanced disease, but whose lung cancer is at high risk of coming back, or in combination with other treatments for patients with advanced disease.

Dr Nigel Blackburn, Cancer Research UK’s Director of drug Development, said: “This vaccine trial is a pioneering approach to improving treatment for lung cancer, the biggest cause of cancer death worldwide.

“By coupling our expertise with a leading biotechnology company, we’ve accelerated the development of this experimental treatment by years.”

Related Articles

Fungus might play role in Crohn’s disease

A fungus commonly found in human hair follicles also resides in the gut and might play a role in Crohn’s disease, it is reported.

April: News in numbers

A breakdown of science news this month, in numbers.

“US misinformation causes epidemic”

The US reported more measles cases in the first two months of this year than in all of 2017, with public health officials blaming “misinformation” for the growing epidemic.

Pioneering studies in paleogenomics

The 18th annual Wiley Prize in Biomedical Sciences will be awarded to Svante Pääbo and David Reich for sequencing the genomes of ancient humans and extinct relatives.

Top